Published in N Engl J Med on November 04, 2012
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A (2013) 1.98
Thrombosis: tangled up in NETs. Blood (2013) 1.85
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Aspirin for preventing venous thromboembolism. N Engl J Med (2013) 0.99
Aspirin for preventing venous thromboembolism. N Engl J Med (2013) 0.98
Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol (2013) 0.98
Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost (2014) 0.97
Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther (2013) 0.97
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation (2013) 0.95
The role of aspirin in the prevention of cardiovascular disease. Clin Med Res (2014) 0.94
Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood (2014) 0.90
Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol (2013) 0.87
Aspirin for primary prevention of cardiovascular disease. Thromb J (2015) 0.82
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs (2014) 0.82
Thrombo-prophylaxis in acutely ill medical and critically ill patients. Indian J Crit Care Med (2014) 0.81
Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. Thromb Res (2015) 0.81
Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med (2012) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.79
Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? World J Gastroenterol (2013) 0.78
Management of venous thromboembolism: an update. Thromb J (2016) 0.78
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag (2015) 0.77
Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study. Thromb Res (2015) 0.76
Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. J Thromb Haemost (2014) 0.75
Aspirin for preventing venous thromboembolism. N Engl J Med (2013) 0.75
Silent pulmonary thromboembolism in neurosurgery patients: Report of 2 cases and literature review. Medicine (Baltimore) (2016) 0.75
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS One (2016) 0.75
[Aspirin does not protect against thrombosis]. Dtsch Med Wochenschr (2013) 0.75
Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited? Thromb J (2015) 0.75
Venous thromboembolism. Aspirin ASPIREs to reduce vascular events after VTE. Nat Rev Cardiol (2012) 0.75
Gastroprotective [6]-Gingerol Aspirinate as a Novel Chemopreventive Prodrug of Aspirin for Colon Cancer. Sci Rep (2017) 0.75
[Not Available]. Rev Clin Esp (Barc) (2013) 0.75
ACP Journal Club. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. Ann Intern Med (2013) 0.75
Assessing the risk of recurrent venous thromboembolism--a practical approach. Vasc Health Risk Manag (2015) 0.75
The management of venous thromboembolism: A practical tool for the front-line clinician. Can Pharm J (Ott) (2017) 0.75
Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. Int J Gen Med (2016) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
Platelet function as a risk factor for venous thromboembolism in the Framingham Heart Study. Thromb Res (2017) 0.75
Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. J Korean Med Sci (2015) 0.75
Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management. Ann Card Anaesth (2015) 0.75
Use of ASA after warfarin for unprovoked VTE. Can Fam Physician (2013) 0.75
An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. BMC Hematol (2015) 0.75
Bleeding Risk Related to Upper Gastrointestinal Endoscopic Biopsy in Patients Receiving Antithrombotic Therapy: A Multicenter Prospective Observational Study. Curr Ther Res Clin Exp (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol (2007) 6.82
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med (2004) 5.76
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Oxygen saturation and outcomes in preterm infants. N Engl J Med (2013) 4.96
Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ (2003) 4.77
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust (2004) 3.34
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst (2006) 3.11
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care (2003) 2.82
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med (2011) 2.80
Medical treatment of peripheral arterial disease. JAMA (2006) 2.76
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 2.73
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 2.69
Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med (2004) 2.65
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol (2012) 2.63
Landscape of cancer clinical trials in Australia: using trial registries to guide future research. Med J Aust (2011) 2.63
Texaco and its consultants. Int J Occup Environ Health (2005) 2.55
Aspirin resistance. Lancet (2006) 2.54
Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet (2009) 2.53
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52
Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med (2006) 2.40
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33
Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation (2007) 2.24
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 2.20
Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust (2005) 2.20
Sensible approaches for reducing clinical trial costs. Clin Trials (2008) 2.20
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst (2009) 2.16
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation (2005) 2.13
Clonidine in patients undergoing noncardiac surgery. N Engl J Med (2014) 2.07
Family acceptance in adolescence and the health of LGBT young adults. J Child Adolesc Psychiatr Nurs (2010) 2.04
Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation (2009) 1.99
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93
Global response to non-communicable disease. BMJ (2011) 1.93
The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital. N Z Med J (2003) 1.91
Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med (2009) 1.85
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82
Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol (2004) 1.81
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75
An effective exercise-based intervention for improving mental health and quality of life measures: a randomized controlled trial. Prev Med (2004) 1.72